NextCure, Inc.
10
3
5
1
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 80/100
40.0%
4 terminated/withdrawn out of 10 trials
20.0%
-66.5% vs industry average
0%
0 trials in Phase 3/4
400%
4 of 1 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (10)
NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer
Role: collaborator
A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors
Role: lead
A Safety, Tolerability and Efficacy Study of NC525 in Subjects With Advanced Myeloid Neoplasms
Role: lead
A Phase 1 Study of LNCB74 in Advanced Solid Tumors
Role: lead
The Study of NC318 Alone or in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung Cancer
Role: collaborator
A Safety and Tolerability Study of NC762 in Subjects With Advanced or Metastatic Solid Tumors
Role: lead
A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants with Advanced Unresectable or Metastatic Solid Tumors
Role: lead
A Safety and Tolerability Study of NC410 in Subjects With Advanced or Metastatic Solid Tumors
Role: lead
A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors
Role: lead
A Safety and Tolerability Study of NC318 in Combination With Chemotherapy for Subjects With Advanced or Metastatic NSCLC
Role: lead
All 10 trials loaded